<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_raon-2017-0059_s_005_w2aab3b7c10b1b6b1aab1c18b1Aa"><h3>Background</h3><p>The majority of rectal cancers are discovered in locally advanced forms (UICC stage II, III). Treatment consists of preoperative radiochemotherapy, followed by surgery 6–8 weeks later and finally by postoperative chemotherapy. The aim of this study was to find out if tumor regression affected long-term survival in patients with localy advanced rectal cancer, treated with neoadjuvant radiochemotherapy.</p></sec><sec id="j_raon-2017-0059_s_006_w2aab3b7c10b1b6b1aab1c18b2Aa"><h3>Patients and methods</h3><p>Patients with rectal cancer stage II or III, treated between 2006 and 2010, were included in a retrospective study. Clinical and pathohistologic data were acquired from computer databases and information about survival from Cancer Registry. Survival was estimated according to Kaplan-Meier method. Significance of prognostic factors was evaluated in univariate analysis; comparison was carried out with log-rank test. The multivariate analysis was performed according to the Cox regression model; statistically significant variables from univariate analysis were included.</p></sec><sec id="j_raon-2017-0059_s_007_w2aab3b7c10b1b6b1aab1c18b3Aa"><h3>Results</h3><p>Two hundred and two patients met inclusion criteria. Median follow-up was 53.2 months. Stage ypT0N0 (pathologic complete response, pCR) was observed in 14.8% of patients. Pathohistologic stage had statistically significant impact on survival (p = 0.001). 5-year survival in patients with pCR was>90%. Postoperative T and N status were also found to be statistically significant (p = 0.011 for ypT and p &lt; 0.001 for ypN). According to multivariate analysis, tumor response to neoadjuvant therapy was the only independent prognostic factor (p = 0.003).</p></sec><sec id="j_raon-2017-0059_s_008_w2aab3b7c10b1b6b1aab1c18b4Aa"><h3>Conclusions</h3><p>Pathologic response of tumor to preoperative radiochemotherapy is an important prognostic factor for prediction of long-term survival of patients with locally advanced rectal cancer.</p></sec></abstract>

BackgroundThe majority of rectal cancers are discovered in locally advanced forms (UICC stage II, III). Treatment consists of preoperative radiochemotherapy, followed by surgery 6–8 weeks later and finally by postoperative chemotherapy. The aim of this study was to find out if tumor regression affected long-term survival in patients with localy advanced rectal cancer, treated with neoadjuvant radiochemotherapy.Patients and methodsPatients with rectal cancer stage II or III, treated between 2006 and 2010, were included in a retrospective study. Clinical and pathohistologic data were acquired from computer databases and information about survival from Cancer Registry. Survival was estimated according to Kaplan-Meier method. Significance of prognostic factors was evaluated in univariate analysis; comparison was carried out with log-rank test. The multivariate analysis was performed according to the Cox regression model; statistically significant variables from univariate analysis were included.ResultsTwo hundred and two patients met inclusion criteria. Median follow-up was 53.2 months. Stage ypT0N0 (pathologic complete response, pCR) was observed in 14.8% of patients. Pathohistologic stage had statistically significant impact on survival (p = 0.001). 5-year survival in patients with pCR was>90%. Postoperative T and N status were also found to be statistically significant (p = 0.011 for ypT and p < 0.001 for ypN). According to multivariate analysis, tumor response to neoadjuvant therapy was the only independent prognostic factor (p = 0.003).ConclusionsPathologic response of tumor to preoperative radiochemotherapy is an important prognostic factor for prediction of long-term survival of patients with locally advanced rectal cancer.

Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy

Radiology and Oncology

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

BackgroundThe majority of rectal cancers are discovered in locally advanced forms (UICC stage II, III). Treatment consists of preoperative radiochemotherapy,...

	Hazard ratio	95% confidence interval	p
ypT	1.307	0.847–2.014	0.226
ypN	1.507	0.935–2.428	0.092
Postoperative stage	1.268	0.793–2.027	0.793
Downstaging (response to preoperative therapy)	2.725	1.4–5.3	0.003

	Median survival [years]	95% confidence interval	p (log rank)
Pooperative stage 0	6.6	6.1–7.1	0.001
pooperative stage I	6.4	5.8–6.9
Pooperative stage II	5.5	4.9–6.1
Pooperative stage III	4.9	4.3–5.6
Pooperative stage IV	3.7	2.8–4.6
ypT0	6.6	6.1–6.7	0.011
ypT1	6.0	5.2–6.9
ypT2	6.1	5.5–6.7
ypT3	5.3	4.8–5.8
ypT4	3.9	2.0–5.8
ypN0	6.1	5.8–6.5	< 0.001
ypN1	5.2	4.4–6.0
ypN2	3.7	3.0–4.4
Preoperative stage II	5.8	5.0–6.6	0.389
Preoperative stage III	5.6	5.1–6.0	0.389

Prognostic significance of tumor regression in locally advanced rectal cancer after preoperative radiochemotherapy

Article Category: Research Article

Published Online: Dec 07, 2017

Page range: 30 - 35

Received: Sep 11, 2017

Accepted: Oct 08, 2017

DOI: https://doi.org/10.1515/raon-2017-0059

© 2018 Mirko Omejc and Maja Potisek

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Figure 1

Figure 2

Results of multivariate analysis

Results of survival analysis